Getting consistent data on your molecular assets on complex in vitro models, such as regulating immune responses, is challenging but it shouldn’t. Our T cells suppression assay by induced regulatory T cells (iTreg) provides the data insights you need into the immune microenvironment.
Our scientists utilized their expertise to create a validated high throughput iTreg suppression assay to investigate the potential impact of your therapeutic candidate in immune regulation with reproducibility. Collaborate with a dedicated team and leverage robust statistical analytics to streamline your research process, saving time and resources.


ImmuSignature™ iTreg suppression assay service

We have created a fast and efficient in vitro functional test to evaluate how compounds affect the function of iTregs (induced regulatory T cells) by enhancing or inhibiting their ability to suppress T effector cells. This assay can be used alongside our previously established iTreg polarization test to understand better compounds' overall impact on the biology of iTregs.

Key advantages:
  • Completion of projects within a short timeframe of 6 weeks
  • Swift and reproducible semi-automated 384-well high throughput assay format
  • Specifically designed for applications in immuno-oncology and autoimmunity
  • Utilization of highly enriched human primary T cells from multiple donors to account for donor-to-donor variability
  • Generation of reliable and quantitative data of high quality
What is an iTreg suppression assay?

Our ImmuSignature™ iTreg suppression assay allows for the quick identification of potential therapeutic candidates capable of regulating the suppression of T effector cells. These candidates undergo screening in a validated and optimized miniaturized setup, ensuring consistent and dependable data. The assay is designed explicitly for evaluating small molecules or biologics. It is performed in a semi-automated high throughput format, bringing us closer to clinical application with substantial data support for the project.

Why use an iTreg suppression assay for drug discovery?

The iTreg suppression assay is an efficient in vitro co-culture method used to evaluate the influence of therapeutic candidates on the modulation of T effector cell suppression through the iTregs. This complex interaction, driven by soluble cytokines, has been shown to regulate the effector component of the adaptive immune system. In the context of immuno-oncology applications, compounds tested in these assays have the potential to disrupt the control exerted by iTregs over effector cells. Conversely, in the case of anti-inflammatory agents, the assay can demonstrate a sustained or enhanced suppression effect.

Primary applications of iTreg suppression assay

In the process of drug screening, the iTreg suppression assay is utilized to assess a drug's ability to hinder the functionality of T effector cells through the interaction with polarized iTreg cells in a co-culture system. This method holds promise for addressing cancer, as suppressing Treg activity could potentially bolster immune responses against tumors. Additionally, this assay enables the evaluation of a drug's capacity to enhance the efficacy of iTregs, which could prove advantageous in the treatment of autoimmune disorders.

How the iTreg suppression assay works


ImmuSignature™ iTreg Suppression Assay setup. Polarized iTreg cells are co-cultured with T effector cells in the presence of therapeutic candidates. T effector cells proliferation and activation are measured by flow cytometry in total CD3+ T cells and CD4+ and CD8+ T cell subsets.